TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07330778: A Study of CDX-622 in Participants With Mild to Moderate Asthma

Sponsor: Celldex Therapeutics · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$633,420

Rescue Site Savings

+$422,280

Unlock Full NCT07330778 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07330778 Rescue Dossier →